Article

What the Diagnostic Radiologist Needs to Know about Radiation Oncology

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins School of Medicine, Baltimore MD 21231, USA.
Radiology (Impact Factor: 6.21). 10/2011; 261(1):30-44. DOI: 10.1148/radiol.11101688
Source: PubMed

ABSTRACT Substantial technologic advances in radiation treatment planning and delivery have made possible exquisite tailoring of three-dimensional radiation dose distributions that conform to the tumor treatment volume while avoiding adjacent normal tissues. Although such highly precise treatment can increase the therapeutic ratio, it also introduces the potential that tumor extension outside the target is missed because it is unrecognized at the time of radiation treatment planning. As a result, accurate targeting of the tumor with radiation is of utmost importance to the radiation oncologist. Communication between diagnostic radiologists and radiation oncologists is essential, particularly given the subtleties that accompany image interpretation, to optimize the care of the cancer patient.

1 Follower
 · 
103 Views
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: Radiation injuries often occur during or after radiation therapy in the abdomen or pelvis. Although any organ in the abdomen or pelvis may be exposed to and injured by radiation therapy directed to a nearby organ, this article focuses on more frequently encountered imaging findings of inadvertent radiation damage. It is important for the radiologist to be familiar with the imaging appearances of inadvertent radiation damage to abdominopelvic viscera in order to sustain clinical relevance and not mistake radiation injuries for other entities.
    Radiologic Clinics of North America 09/2014; 52(5):1041-1053. DOI:10.1016/j.rcl.2014.05.004 · 1.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE. The purpose of this study is to evaluate the safety and complications of CT-guided implantation of intrahepatic fiducial markers for proton beam therapy. MATERIALS AND METHODS. In this retrospective study, we reviewed 69 patients who underwent 149 percutaneous fiducial marker implantations for primary and metastatic hepatic tumors from April 2007 through July 2013. The implantations enabling satisfactory treatment planning and CT simulation were considered as technically successful. Major and minor procedure-related complications during and after fiducial marker implantation were documented. RESULTS. The success rate of fiducial marker implantation was 99.3% (148/149). In one patient, a fiducial marker migrated into the vascular system, which was realized during the procedure and required reimplantation. None of the patients was required to return for additional implantations. The major and minor complication rates were 0% and 2.9% (2/69), respectively. Both minor complications included small pneumothorax not requiring hospital admission. CONCLUSION. CT-guided placement of gold fiducial markers is associated with a high technical success rate with few complications, which is an essential step in the overall treatment planning and performance of proton beam therapy for the management of hepatic tumors.
    American Journal of Roentgenology 02/2015; 204(2):W207-W213. DOI:10.2214/AJR.14.12901 · 2.74 Impact Factor